Generali Asset Management SPA SGR Purchases 6,433 Shares of Boston Scientific Corporation $BSX

Generali Asset Management SPA SGR boosted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 7.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 89,738 shares of the medical equipment provider’s stock after acquiring an additional 6,433 shares during the period. Generali Asset Management SPA SGR’s holdings in Boston Scientific were worth $8,761,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of BSX. Norges Bank purchased a new stake in shares of Boston Scientific during the 2nd quarter valued at $2,089,937,000. Edgewood Management LLC acquired a new position in Boston Scientific during the 2nd quarter valued at about $746,655,000. Bessemer Group Inc. raised its stake in Boston Scientific by 14,391.8% in the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock valued at $313,618,000 after buying an additional 2,899,653 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Boston Scientific by 1.9% in the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after acquiring an additional 2,545,381 shares in the last quarter. Finally, Bank of Nova Scotia grew its stake in shares of Boston Scientific by 106.4% during the second quarter. Bank of Nova Scotia now owns 3,025,519 shares of the medical equipment provider’s stock worth $324,971,000 after acquiring an additional 1,559,605 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Down 0.7%

NYSE:BSX opened at $95.29 on Friday. The firm has a market capitalization of $141.26 billion, a P/E ratio of 50.96, a PEG ratio of 1.92 and a beta of 0.67. The company’s fifty day moving average price is $98.05 and its 200-day moving average price is $100.97. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period last year, the firm earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In related news, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 93,095 shares of company stock valued at $9,305,450. 0.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on BSX shares. Truist Financial decreased their price objective on shares of Boston Scientific from $130.00 to $120.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and upped their price target for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Barclays upped their target price on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Finally, BTIG Research reaffirmed a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research report on Friday, November 21st. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and a consensus target price of $124.85.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.